AKT1 and thyroid cancer: 2.5. DSF/Cu Improves the Response of BRAFV600E-Mutated Thyroid Cancer Cells to PLX4032 by Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Signaling Pathways